ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by Invesco Ltd.

Invesco Ltd. lessened its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 10.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 197,545 shares of the specialty pharmaceutical company's stock after selling 22,814 shares during the quarter. Invesco Ltd. owned approximately 0.94% of ANI Pharmaceuticals worth $10,920,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in ANIP. JPMorgan Chase & Co. grew its holdings in shares of ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock worth $33,101,000 after buying an additional 340,854 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in ANI Pharmaceuticals by 14.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company's stock worth $854,000 after acquiring an additional 1,972 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of ANI Pharmaceuticals by 4.2% in the 3rd quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company's stock valued at $25,373,000 after purchasing an additional 17,314 shares in the last quarter. Barclays PLC grew its holdings in shares of ANI Pharmaceuticals by 1,681.2% during the 3rd quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company's stock worth $8,534,000 after purchasing an additional 135,003 shares during the period. Finally, Franklin Resources Inc. raised its holdings in ANI Pharmaceuticals by 6.1% in the third quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company's stock valued at $705,000 after buying an additional 691 shares during the period. Institutional investors and hedge funds own 76.05% of the company's stock.

ANI Pharmaceuticals Stock Up 1.3 %

NASDAQ ANIP traded up $0.93 during trading hours on Monday, reaching $70.75. 1,089,005 shares of the company traded hands, compared to its average volume of 277,019. The company has a 50 day moving average of $64.46 and a two-hundred day moving average of $59.99. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $71.85. The stock has a market capitalization of $1.54 billion, a PE ratio of -128.64 and a beta of 0.49.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,000 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now directly owns 66,525 shares in the company, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Meredith Cook sold 400 shares of the stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $68.96, for a total transaction of $27,584.00. Following the completion of the sale, the vice president now directly owns 80,145 shares in the company, valued at approximately $5,526,799.20. This trade represents a 0.50 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,200 shares of company stock worth $197,792. 12.70% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ANIP. Truist Financial raised their target price on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research note on Monday, April 21st. Jefferies Financial Group initiated coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They set a "buy" rating and a $80.00 target price on the stock. StockNews.com downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday. Guggenheim reiterated a "buy" rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, April 11th. Finally, JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price target for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $80.13.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.